Tempus AI (NASDAQ:TEM) Stock Price Down 7.8% – What’s Next?

Shares of Tempus AI, Inc. (NASDAQ:TEM) traded down 7.8% on Friday. The stock traded as low as $70.55 and last traded at $69.9910. 808,135 shares traded hands during trading, a decline of 87% from the average session volume of 6,219,010 shares. The stock had previously closed at $75.89.

Wall Street Analyst Weigh In

Several analysts recently weighed in on TEM shares. Cantor Fitzgerald raised their price objective on Tempus AI from $80.00 to $92.00 and gave the company an “overweight” rating in a research note on Tuesday, November 3rd. UBS Group initiated coverage on shares of Tempus AI in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $70.00 price target on the stock. Canaccord Genuity Group lifted their price target on shares of Tempus AI from $80.00 to $95.00 and gave the company a “buy” rating in a report on Monday, October 12th. Roth Capital started coverage on shares of Tempus AI in a research report on Tuesday, September 8th. They set a “neutral” rating and a $67.00 price objective for the company. Finally, Guggenheim raised their target price on shares of Tempus AI from $65.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Eleven equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Tempus AI has a consensus rating of “Hold” and an average target price of $79.37.

Tempus AI Trading Down 8.0%

The company has a market cap of $12.74 billion, a price-to-earnings ratio of -65.86 and a beta of 3.61. The business’s fifty day moving average price is $72.70 and its 200 day moving average price is $57.51. The company has a debt-to-equity ratio of 2.70, a current ratio of 2.61 and a quick ratio of 2.48.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Monday, November 2nd. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.16. The company had revenue of $411.54 million during the quarter, compared to the consensus estimate of $409.39 million. Tempus AI had a negative return on equity of 47.00% and a negative net margin of 12.54%. The firm’s revenue was up 23.1% compared to the same quarter last year. During the same period last year, the company earned ($0.46) earnings per share. Research analysts anticipate that Tempus AI, Inc. will post -1.20 earnings per share for the current fiscal year.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, CAO Ryan Bartolucci sold 7,062 shares of Tempus AI stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total value of $529,650.00. Following the completion of the sale, the chief accounting officer directly owned 60,804 shares in the company, valued at approximately $4,560,300. The trade was a 10.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Epstein sold 370 shares of the stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $74.29, for a total value of $27,487.30. Following the transaction, the director owned 30,474 shares in the company, valued at $2,263,913.46. The trade was a 1.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,237,227 shares of company stock valued at $85,388,983 over the last ninety days. Insiders own 24.26% of the company’s stock.

Institutional Investors Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. V Square Quantitative Management LLC bought a new position in shares of Tempus AI during the 3rd quarter worth about $27,000. Edmond DE Rothschild Holding S.A. bought a new stake in Tempus AI in the 3rd quarter valued at about $33,000. EMC Capital Management bought a new stake in Tempus AI in the 2nd quarter valued at about $29,000. Ulland Investment Advisors LLC acquired a new position in Tempus AI during the 3rd quarter worth approximately $41,000. Finally, Heritage Family Offices LLP acquired a new position in Tempus AI during the 3rd quarter worth approximately $45,000. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.